Craft
Merus

Merus

Total Funding

$149.3 M

Merus Summary

Company summary

Overview
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The Company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.
Type
Private
Status
Active
Founded
2003
HQ
Utrecht, NL | view all locations
Website
http://www.merus.nl/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Bill Lundberg

    Bill Lundberg, President, Chief Executive Officer & Principal Financial Officer, Executive Director

    • Andrew Joe

      Andrew Joe, SVP & Chief Medical Officer

      • John de Kruif

        John de Kruif, SVP & Chief Technology Officer

        • Mark Iwicki

          Mark Iwicki, Non-Executive Director

          LocationsView all

          2 locations detected

          • Utrecht, Utrecht HQ

            Netherlands

            62 Yalelaan

          • Cambridge, MA

            United States

            139 Main St #302

          Footer menu